Vancouver, B.C.   – MYM Nutraceuticals Inc. (CSE:MYM) (OTC:MYMMF), is extremely pleased to announce that it has acquired the brand “Joshua Tree”, which includes the acquisition of the domains;

jtree.com
jtree.ca
joshuatreecbd.com
joshuatree.life

MYM has also filed trademark applications in the USA and Canada for Joshua Tree and plans to completely re-brand MYM owned CBD brand “HempMed”. The new Joshua Tree product line will be launched this year in Canada, USA and Europe and will include up to 5 new innovative CBD products.

“This is the first step in our international expansion of our CBD products,” commented Rob Gietl, CEO of MYM, “Our unique and effective formulations are the best in breed and our rapid sales growth demonstrate the vast consumer demand for our products.”

Due to an explosion of consumer interest and numerous respected medical studies on the benefits of high quality hemp CBD products, the CBD nutraceutical market is rapidly growing worldwide. A recent Forbes magazine article estimated that the CBD market will grow to a $2.1 billion market in consumer sales by 2020 with $450 million of those sales coming from hemp-based sources. That’s a 700% increase from 2016.

The current HempMed (soon to be “Joshua Tree”) product line currently consists of over 20 Hemp products and plan to launch several more groundbreaking products over the next 12 months as a direct result of the transaction. MYM plans on expanding HempMed’s existing distribution network which consists of over 60 retail outlets and online sales portals across Canada, the USA, and Internationally. Furthermore, MYM has built a brand-new, robust eCommerce website to drive online sales. The current Product line includes signature tinctures, concentrates and oils, edibles, vape products and a line of fast growing pet CBD products which will join the multi-billion-dollar pet market.

MYM is continuing to negotiate acquisitions of complimentary businesses and assets in the technology, Nutraceuticals and CBD nutraceutical sector and is currently in talks with other innovative companies.

MYM Nutraceuticals Inc. (CSE:MYM)(OTC:MYMMF)(FRA:OMY) is a public company trading on the Canadian Stock Exchange whose primary focus is developing high-end organic medicinal cannabis supplements and topical products. MYM also has an interest in the development of high-density farming facilities and technologies that allow MYM to expand its brand into the global market.

ON BEHALF OF THE BOARD

“Rob Gietl”

Rob Gietl, CEO
MYM Nutraceuticals Inc.
www.mymarijuana.ca

MYM Investor Relations Contact info:
Terry Brown
Tel: 1-855-696-2261

You can email Mr. Brown here: http://www.mymarijuana.ca/contact-us/

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.